RxDoctor Payments Data

Gregg Reis, MD

Interventional Cardiology · Hanover, PANPI 1134100167

Payments from drug & device makers

$3,514in general payments, 2019–2025

Across 70 payments — averaging $50.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$932
  • Abiomed$579
  • Inari Medical, Inc.$284
  • Abbott$275
  • Johnson & Johnson$177
  • Sanofi-aventis U.S. LLC$160
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$97528%
  • Food & beverage$2,53972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,514 in reported general payments places this provider in the 25th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$161,742
Medicare patients
668
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban501$525,831
JardianceEmpagliflozin178$163,907
XareltoRivaroxaban94$100,934
EntrestoSacubitril/Valsartan70$92,338
Repatha SureclickEvolocumab71$54,831
Praluent PenAlirocumab35$27,645
BrilintaTicagrelor15$14,410
Metoprolol Succinate704$10,564
Ezetimibe390$7,840
Rosuvastatin Calcium567$5,440
Atorvastatin Calcium386$4,138
Ranolazine ErRanolazine58$3,838
Dabigatran EtexilateDabigatran Etexilate Mesylate24$3,177
Losartan Potassium308$2,559
Spironolactone250$2,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$525,831501 claims
Boehringer IngelheimJardiance$59$163,907178 claims
Johnson & JohnsonXarelto$177$100,93494 claims
NovartisEntresto$62$92,33870 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →